A citation-based method for searching scientific literature

Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell, Susanna Y-S Cheng, Helge G Bischoff, Nir Peled, Francesco Grossi, Ross R Jennens, Martin Reck, Rina Hui, Edward B Garon, Michael Boyer, Belén Rubio-Viqueira, Silvia Novello, Takayasu Kurata, Jhanelle E Gray, John Vida, Ziwen Wei, Jing Yang, Harry Raftopoulos, M Catherine Pietanza, Marina C Garassino. N Engl J Med 2018
Times Cited: 2818



Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
Times Cited: 4161




List of shared articles



Times cited

The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015.
Andrew G Nicholson, Ming S Tsao, Mary Beth Beasley, Alain C Borczuk, Elisabeth Brambilla, Wendy A Cooper, Sanja Dacic, Deepali Jain, Keith M Kerr, Sylvie Lantuejoul,[...]. J Thorac Oncol 2022
18

Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study.
Geoffroy Bilger, Nicolas Girard, Hélène Doubre, Matteo Giaj Levra, Etienne Giroux-Leprieur, Frederique Giraud, Chantal Decroisette, Matthieu Carton, Marie Ange Massiani. Cancer Immunol Immunother 2022
1

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.
O Molinier, B Besse, F Barlesi, C Audigier-Valette, S Friard, I Monnet, G Jeannin, J Mazières, J Cadranel, J Hureaux,[...]. ESMO Open 2022
1

Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study.
Mette T Mouritzen, Karen F Junker, Andreas Carus, Morten Ladekarl, Peter Meldgaard, Anders W M Nielsen, Anna Livbjerg, Jacob W Larsen, Halla Skuladottir, Charlotte Kristiansen,[...]. Acta Oncol 2022
2

Tumour microenvironment and heterotypic interactions in pancreatic cancer.
Raúl Muñoz Velasco, Ana García García, Paula Jiménez Sánchez, Inmaculada Montanuy Sellart, Víctor Javier Sánchez-Arévalo Lobo. J Physiol Biochem 2022
0

Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis From Non-Small Cell Lung Cancer.
Yuchang Wang, Rui Chen, Yue Wa, Shikuan Ding, Yijian Yang, Junbo Liao, Lei Tong, Gelei Xiao. Front Immunol 2022
0

PD-1/L1 inhibitors may increase the risk of pericardial disease in non-small-cell lung cancer patients: a meta-analysis and systematic review.
Honglin Li, Deting Han, Lei Zhang, Xiaoteng Feng, Huijie Li, Feiran Yang, Lucheng Song, Xiurong Li. Immunotherapy 2022
0

A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer.
Kai Wu, Yifan Fu, Daxiong Zeng, Tao Chen, Changguo Wang, Junhong Jiang. J Thorac Dis 2022
0

Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China.
Xiao Han, Jun Guo, Xiaoyong Tang, Hui Zhu, Dongyuan Zhu, Xiqin Zhang, Xiangjiao Meng, Ying Hua, Zhongtang Wang, Yan Zhang,[...]. J Cancer Res Clin Oncol 2022
1

Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1.
Takeshi Masuda, Kazunori Fujitaka, Tomoko Suzuki, Kosuke Hamai, Naoko Matsumoto, Mirai Matsumura, Shoko Isoyama, Sayaka Ueno, Mineyo Mito, Kakuhiro Yamaguchi,[...]. Thorac Cancer 2022
0